newsfilter
← Latest News
GlobeNewswire·

Aura Biosciences Reports Third Quarter 2024 Financial Results and Business Highlights

Positive Phase 2 End of Study Data with Bel-sar in Early-Stage Choroidal Melanoma; Ongoing Phase 3 CoMpass Trial Recently Received Authorization to Start Enrolling Patients in Europe Multiple Clinical Complete